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Retinal, vitreous humor, brain, and cerebrospinal fluid (CSF) foscarnet levels were measured by high-
performance liquid chromatography after administration of an intravenous dose of 120 mg/kg of body weight
to 32 pigmented rabbits. A pharmacokinetic analysis was done using a two-compartment model. The penetra-
tion ratios, defined as ratios of retinal, vitreous humor, brain, and CSF areas under the concentration-time
curve from 0 to 2 h were 110% 6 1%, 12.3% 6 0.7%, 118% 6 1%, and 20.2% 6 2.2%, respectively. These results
suggest a good penetration of foscarnet into the retinal and brain tissues, reaching higher concentrations than
those estimated from vitreous humor and CSF levels.
Foscarnet is a drug used extensively in the treatment of
retinitis and neurological conditions caused by cytomegalovi-
rus (CMV) in patients with AIDS, and there are data support-
ing the use of foscarnet with aciclovir or ganciclovir in the
treatment of retinitis caused by other herpesviruses (4, 15, 19).
It has been suggested that intravenous ganciclovir or foscarnet
maintenance therapy of CMV retinitis may result in subthera-
peutic intraocular concentrations, a factor implicated in the
progression of this disease (1). However, there are few data on
concentrations of foscarnet in tissue, and the levels in retina or
brain have not been described for either humans or experi-
mental models. The intraocular penetration of foscarnet has
been assessed only in vitreal samples from a few patients with
CMV retinitis (1). Likewise, the penetration of foscarnet into
the central nervous system has been evaluated only from single
determinations in cerebrospinal fluid (CSF) and single ratios
of concentrations in CSF to concentrations in plasma in sam-
ples obtained at variable and arbitrary intervals from patients
with nonuniform dosages. Consequently, the results have been
very variable, 13 to 340% of the simultaneous concentration in
plasma (11, 21–23). Moreover, to assume that retinal and brain
foscarnet levels are similar to those measured in vitreous hu-
mor and CSF may be erroneous. Due to the difficulties in
obtaining tissue samples from humans, we used a rabbit model
for evaluating the retinal and brain penetration of foscarnet
after its intravenous administration. The ratios of the areas
under the concentration-time curve (AUCs) for tissues and
CSF to the AUCs for serum were used to obtain more accurate
results (16). We have also determined whether the concentra-
tions detected in retina and brain are similar to those in vitre-
ous humor and CSF. In humans, no significant differences were
observed in plasma concentrations between single- and multi-
ple-dose administration (25); therefore, the study was designed
to obtain samples after a single dose of the drug.
Study design, drug administration, and sampling. Thirty-
two healthy, pigmented rabbits with a mean weight of 3 kg
were used. The study was conducted according to the Minis-
terio de Agricultura guidelines. After animals were anesthe-
tized with an intramuscular injection of xylazine (12 mg/kg of
body weight) and ketamine (60 mg/kg), a jugular vein was
catheterized by a surgical procedure and maintained as per-
meable by a 0.9% saline solution-lock technique. The entire
experiments were conducted under surgical anesthesia. Each
rabbit received 120 mg of foscarnet (Astra Pharmaceutical,
Södertälje, Sweden) per kg, as an intravenous dose over a
3-min period, since this is a usual dose in humans during the
maintenance treatment of CMV retinitis in patients with
AIDS. Blood (2 ml) was taken before and at 5, 15, 30, 45, 60,
75, 90, and 120 min after the end of infusion. Retina, vitreous
humor, brain, and CSF samples were obtained at 30 and 90
min and 60 and 120 min, so that each animal yielded tissue
data for two different time points, before being euthanatized
with intravenous pentobarbital. Vitreous humor was obtained
by cutting the eyes just behind the lens (mean volume ob-
tained, 638 6 184 ml); afterwards, the retina was carefully
dissected (mean weight obtained, 49.3 6 13.5 mg). Brain tissue
was obtained through a small craniectomy (mean weight ob-
tained, 596 6 169 mg), and CSF was obtained by puncture of
the cisterna magna (mean volume obtained, 528 6 193 ml).
After centrifugation, plasma and CSF samples were stored at
280°C until testing. Before being frozen, vitreous humor and
retinal and brain tissues were sonicated at 0.5 cps for 40 s
(50-W sonicator; Sonics & Materials Inc., Danbury, Conn.).
For processing, each sample was transferred to a microparti-
tion tube (Centricon 30; Amicon Inc., Beverly, Mass.) and
centrifuged at 1,500 3 g for 20 min.
Assay procedure. Concentrations of foscarnet were deter-
mined according to the modified method of Pettersson and
Nordgren (20), using a high-performance liquid chromato-
graph with an electrochemical detector (Gilson Medical Elec-
tronics, Inc., Middleton, Wis.). The analytical column (125 by
4 mm [inside diameter]) was a Lichospher 100 RP-18 with
5-mm particles (Merck, Darmstadt, Germany). The volume
injected was 20 ml, and the flow rate was 0.7 ml/min. Quanti-
fication was based on measuring standard solutions of foscar-
net (Astra Pharmaceutical) in 0.9% (wt/vol) NaCl solution and
hydrochlorothiazide as the internal standard. The detection
limit was 10 mg/ml. Calibration lines were linear (rxy . 0.9000)
over a range of 10 to 1,200 mg/ml. An analysis of variance was
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carried out to determine interassay [F(1–27) 5 0.84; P 5
0.5343] and intra-assay [F(1–37) 5 0.72; P 5 0.6692] variabil-
ity; no statistically significant differences were observed be-
tween them. The intra- and interassay coefficients of variation
were 1 and 1.7%, respectively. Recovery of foscarnet from
plasma, retina, vitreous humor, brain, and CSF, after adding
known concentrations of foscarnet to them, was 86, 82.7, 79.8,
84, and 94.8%, respectively.
Pharmacokinetic analysis. Compartmental pharmacokinetic
parameters were calculated from the concentration-time curve
data (12). The corresponding macroconstants were calculated
from the biexponential equation Cst 5 A0e
2at 1 B0e
2bt, where
Cst is the concentration of the drug in serum at time t. A0 and
B0, and a and b, are the intercepts and exponents, respectively,
of the two exponential phases. Twenty data per time point
were used to determine the serum pharmacokinetic parame-
ters, which were calculated manually, and 8 to 10 data for each
tissue per time point were used. The AUC from 0 h to infinity
(AUC0–`) was calculated up to the time of the last quantifiable
serum concentration using the trapezoidal rule and then to
infinity using the quotient of the last measurable concentration
to the terminal-phase rate constant, which was calculated by
the above-mentioned curve fitting. Results were expressed per
milliliter, assuming tissue densities as 1. The penetration ratio
was defined as the ratio of the AUC0–2 for tissues and CSF to
the AUC0–2 for serum.
Results. Figure 1 shows the mean serum and tissue concen-
tration-time curves after the intravenous administration of fos-
carnet (120 mg/kg). The data fitted to a two-compartment
model, the equation being Cst 5 0.49e
210.02t 1 0.382e20.636t.
The profile clearly shows the two distinct phases associated
with a two-compartment model. The a phase is basically the
rapid distribution of the drug (A/a , B/b), while the b phase
is basically its elimination, after reaching the stationary equi-
librium state. Foscarnet has a rapid disappearance from serum
with a mean a-phase half-life of 0.065 6 0.001 h and a b-phase
half-life of 1.09 6 0.26 h. Table 1 summarizes the values of the
pharmacokinetic parameters for foscarnet obtained with this
model.
High levels of foscarnet were found in retina and brain, with
AUC0–2 of 532 6 183 and 574 6 202 mg z h/ml, respectively.
Penetration into both the retina and the brain was remarkably
high, with estimated penetration ratios of 110% 6 1% and
118% 6 1%, respectively. Lower levels of foscarnet were found
in vitreous humor and CSF, with AUC0–2 of 59.7 6 23.0 and
93 6 1.8 mg z h/ml and penetration ratios of 12.3% 6 0.7% and
20.2% 6 2.2%, respectively.
Discussion. In this model, the estimated distribution vol-
umes suggest that foscarnet is a drug widely distributed in
different organs, as deduced from the equation Vss/Vc 2 1 5
0.96 (12), where Vss is volume of distribution at steady state
and Vc is volume of distribution in central compartment, in
spite of a short biological half-life in both a and b phases. Our
data show that foscarnet has a good penetration in both retinal
and brain tissues, reaching levels far above the 50% inhibitory
concentration (120 mg/ml; range, 7.5 to 240) for most strains of
FIG. 1. Mean (6 standard deviation; micrograms per milliliter) serum and tissue concentration-time curves after an intravenous dose of foscarnet (120 mg/kg).
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human CMV (7). Foscarnet is a very small and highly nega-
tively charged molecule, with a protein binding level of 15%
and with an organic/water partition coefficient of 0.426 (3).
These physicochemical properties would facilitate its diffusion
through the blood-brain and blood-retinal barriers (17). These
high ratios may also be due to a slower elimination from retina
and brain than from serum, so that the ratio of drug concen-
trations in these tissues and serum increases with time after
infusion, as frequently occurs with other drugs (13, 16). How-
ever, the concentrations and AUC0–2 observed in the vitreous
humor are much lower than those in the retina. Thus, the
retinal concentrations reached after the intravenous adminis-
tration of foscarnet cannot be estimated from those observed
in the vitreous humor.
In the same way, levels of foscarnet in CSF are lower than
those observed in brain. CSF drug concentrations are fre-
quently lower than those of the cerebral extracellular fluid and
the brain tissue, overall when CSF is obtained from ventricles
or the cisterna magna (6, 18, 26). However, the presence of an
AUC in the brain sixfold higher than that in the CSF suggests
that, at least in this animal, there may be a high efflux clearance
of foscarnet from CSF. This could be produced via the arach-
noid villi and nonarachnoidal CSF drainage pathways (cribi-
form area, orbital area, and inner ear) present in the rabbit and
other lower mammals (8, 15). In addition, as foscarnet is a
weak acid (9), there could be an active efflux from the CSF, as
occurs with other weak organic acid drugs (5).
Although the intravitreal levels of foscarnet observed in the
patients studied by Arevalo et al. (1) were similar to those we
have found in rabbits, it is difficult to know whether our data
are entirely applicable to humans since the few reported phar-
macokinetic studies of foscarnet in humans have been carried
out with heterogeneous doses, rates of perfusions, and phar-
macokinetic analyses. It would be expected that the concen-
trations of foscarnet in these tissues would be similar to or
higher than those observed in rabbits, since in humans the Vss
of foscarnet is higher and the half-life is longer than those in
rabbits (2, 24, 26).
From our study, it cannot be ruled out that the current
dosages of foscarnet during the maintenance phase of CMV
retinitis (90 to 120 mg/day, in a single dose) give rise to sub-
therapeutic concentrations in the retina during part of the day
and that this may be a factor in the progression of the disease.
Nevertheless, our results show that foscarnet penetrates well
into the retina and brain tissue, reaching higher concentrations
than those estimated from vitreous humor and CSF.
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